2017 Annual Report - Bay Medical...Cancer Registry Data Summary of 2016 Statistics In 2016, the...

2017CancerProgramReport

BayMedicalSacredHeartHealthSystem|2017CancerProgramReport 1

CancerProgramReport2017

B AY M E D I C A L C E N T E R S A C R E D H E A R T H E A LT H S Y S T E M

TheBayMedicalCancerProgramisaComprehensiveCommunityCancerProgramthathas

been accreditedby theAmericanCollegeof SurgeonsCommissiononCancer since 1997.

The program is guided by the leadership of a multidisciplinary Cancer Committee. This

CommitteeprovidesdirectionandreviewofcancercareandservicesatBayMedical.

Cancer education, prevention and screening are fundamental functions of the program,

withacommitmenttoimprovethehealthandwell-beingofpatients,communitymembers

and staff. In collaboration with numerous healthcare professionals on staff as well as

community partners, a variety of events and activities were offered in 2017. These

opportunitiesweredevelopedwith a focus onCommitteeprioritized topics andhigh risk

groups. Throughout the year, lung cancer screeningwas available through theuseof the

Low-DoseCTthoraxscreeningwiththe128-sliceCTScanner.Thebroadarrayofactivities

providingeducation forpreventionandscreening in2017 includedtheannualHealthFair

withamedicaloncologistasaneducationalspeaker;aColonCancerSeminar;SkinCancer

Screenings; Relay for Life; Look Good, Feel Better classes; a Mammogram Awareness

Campaign;MakingStridesAgainstBreastCancersponsorship;aWomen’sHealthFairwith

520 registered attendees; participation in the Great American Smoke-out; and the

distributionofeducationalcommunicationsviamultiplemediavenues.

RelayforLife


CancerRegistry

TheBayMedicalSacredHeartCancerRegistryprovidesdatamanagementservicesforstate

andnational cancer case incidence and cancer survival data; analyzes statistics for quality

purposes;meetsdatarequestsofclinicians,administrators;andmaintainscompliancewith

statereportingregulations.

TheCancerRegistryatBayMedicalwasestablishedwithareferencedateofJanuary1,1999.

In 2017, the Registry received the 2016 Jean Byers Award for Excellence in Cancer

RegistrationfromtheFloridaCancerDataSystem(FCDS).

TheRegistryisresponsibleforcollecting,managing,andanalyzingcancerdata.Incompliance

with the standards of the American College of Surgeons, Commission on Cancer, lifetime

follow-up ismaintainedonallanalyticcases (casesnewlydiagnosedand/or treatedatBay

Medical).Follow-upprovidesasourcefortrackingoutcomesandsurvivalstatistics.

StatisticalreportsfromtheRegistryareutilizedtostudytreatmentoutcomes,evaluatethe

qualityofpatientcare,assistinformulatingcancerpreventionandscreeningprogramsand

administrativeplanning,andevaluatecommunityhealthinitiatives.

CancercasesaresubmittedtotheFloridaCancerDataSystemasrequiredbystatelaw.All

analytic casesare reportedannually to theNationalCancerDataBase (NCDB)andeligible

casesarereportedmonthlytotheRapidQualityReportingSystem(RQRS),asrequiredofan

approvedcancerprogrambytheAmericanCollegeofSurgeonsCommissiononCancer.

CancerRegistryData

Summaryof2016StatisticsIn 2016, the Registry added 679 new cases into the database.Of these, 516 cancer cases

seenatBayMedicalSacredHeartwereanalytic.Theanalytictopprimarycancersiteswere

lung, breast, colorectal, non-Hodgkin lymphoma, melanoma, bladder, and thyroid. These

sites account for 69% of the newly diagnosed and/or treated cancers seen in 2016. The

remaining cases were new to Bay Medical and treated with active disease (non-analytic

cases).


Astatisticalreviewofthemajorsitesofcanceralongwithareviewofthecalendaryear is

includedasfollows:

26.2%

14.7%

12.6%

5.0%

3.5%

3.5% 3.5%

MajorSites2016AnalyticCases

Lung

Breast

Colorectal

Non-HodgkinLymphoma

Melanoma,Skin

Bladder

Thyroid

Male- 246

, 47.7%

Female-270,52.3%

GenderDistribution2016AnalyticCases


0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Lung Colorectal Breast NHL Melanoma

Bladder Thyroid

Male 50% 64% 1% 80% 67% 72% 28.0% Female 50% 36% 99% 20% 33% 28% 72.0%

TopFivePrimarySitesbyGender2016AnalyticCases

0%

5%

10%

15%

20%

25%

30%

Lung Breast Colorectal NHL Melanoma BladderBMSH 26% 15% 13% 5% 4% 4% FL 14% 14% 8% 4% 5% 5% USA 13% 15% 8% 4% 5% 5%

BayMedicalMostFrequentCancerIncidenceComparedtoState&NationalIncidenceEstimates,2016


SiteDistributionofNewlyDiagnosedAnalyticCases,2016

TOTAL MALE FEMALE

OralCavity&Pharynx 6 6 0 DigestiveSystem 107 70 37 RespiratorySystem 139 70 69 Bone&Joints 1 1 0 SoftTissue 4 2 2 Skin,ExcludingBasal&Squamous 18 12 6 Breast 76 1 75 FemaleGenitalSystem 28 0 28 MaleGenitalSystem 7 7 0 UrinarySystem 34 26 8 Brain&OtherNervousSystem 25 12 13 EndocrineSystem 20 5 15 Lymphoma 28 16 12 Leukemia 4 3 1 Mesothelioma 2 2 0 Unknown/Other

17

13

4


ColonCancerStudyEvidence points to improved rates of curative secondary treatment after detection of a

recurrence in patients who participate in a surveillance program after initial curative

resection of colon cancer. The success of surveillance for early detection of curable

recurrencedependsonpatientandprovideradherencetorecommendedschedules.1

In order to evaluate follow-up colon cancer surveillance schedules, a 2017 study on

colonoscopies for colon cancer cases diagnosed and treated at BayMedical in 2016 was

conductedtoevaluatethecarepatientsreceived.

TheNationalComprehensiveCancerNetwork(NCCN)Guidelinesspecifythatcolonoscopies

should be performed one year after resection or at 3 to 6 months post resection if not

performedpreoperativelybecauseofanobstructing lesion. TheQualityOncologyPractice

Initiative (QOPI) and the American Society of Clinical Oncology (ASCO) specify that

colonoscopies should be performed before or within 6 months of curative colorectal

resectionorcompletionofprimaryadjuvantchemotherapy.

Allcoloncancercasesdiagnosedin2016werereviewed.Findingsconcludedthatalleligible

patientsreceivedtheappropriatetreatmentaccordingtotheabovesurveillanceguidelines.1Practice Guidelines for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer;TheAmericanSocietyofColon&RectalSurgeons.2015.

AccountabilityandQualityImprovementMeasures

BayMedicalSacredHeartparecipates in theRapidQualityReporengSystem(RQRS)of the

AmericanCollegeofSurgeons.RQRSisareporengandqualitytoolusedtoproviderealeme

assessment of the program’s adherence to quality cancer measures for various types of

cancer. This allows physicians to track clinical performance on naeonal quality indicators.

Parecipaenginthisacevityonamonthlybasisprovidesamethodtoevaluatecareinaemely

manneranddevelopappropriatequalityimprovements.


Another way care is evaluated by the Cancer Commifee is through parecipaeon in the

CancerProgramPraceceReports (CP3R)naeonalbenchmarkingprogramfromtheNaeonal

Cancer Database and supported by the American College of Surgeons. The performance

ratesofcarereceivedbypaeentswithbreast,colon,gastric,lung,andrectalcancerwhohave

documentaeon of treatment are compared to naeonal standard of care guidelines and

evidence-basedpracece.ThegoalsforthestandardsaresetforthbytheAmericanCollegeof

SurgeonsCommissiononCancer(CoC).

BayMedicalSacredHeartPerformance:Allstandardswithapplicablecaseswerecompliant

forthemostrecentyearevaluatedbeingeitheratorexceedingtheestablishedstandardgoal

/performanceratepercentagebelowasspecifiedbytheCoC.

Breast

Standard:Radiaeon isadministeredwithin1year(365days)ofdiagnosis forwomenunder

age70receivingbreastconservaeonsurgeryforbreastcancer.CoCStandard:90%

Standard: Tamoxifen or third generaeon aromatase inhibitor is recommended or

administeredwithin1year(365days)ofdiagnosis forwomenwithAJCCT1corStage IB-III

hormonereceptorposievebreastcancer. CoCStandard:90%

Standard: Radiaeon therapy is recommended or administered following any mastectomy

within1year(365days)ofdiagnosisofbreastcancerforwomenwith>=4posieveregional

lymphnodes. CoCStandard:90%

Standard: Image or palpaeon-guided needle biopsy to the primary site is performed to

establishdiagnosisofbreastcancer. CoCStandard:80%

Colon

Standard: At least 12 regional lymph nodes are removed and pathologically examined for

resectedcoloncancer. CoCStandard:85%


Gastric

Standard: At least 15 regional lymph nodes are removed and pathologically examined for

resectedgastriccancer. CoCStandard:80%

Lung

Standard:Systemicchemotherapyisadministeredwithin4monthstodaypre-operaevelyor

day of surgery to 6 months postoperaevely, or it is recommended for surgically resected

caseswithpathologiclymphnode-posieve(pN1)and(pN2)NSCLC.CoCStandard:85%

Standard:SurgeryisnotthefirstcourseoftreatmentforcN2,M0lungcases.

CoCStandard:85%

Rectum

Standard:PreoperaevechemoandradiaeonareadministeredforclinicalAJCCT3N0,T4N0,

or Stage III; or postoperaeve chemo and radiaeon are administered within 180 days of

diagnosisforclinicalAJCCT1-2N0withpathologicAJCCT3N0,T4N0,orStageIII;ortreatment

isrecommended;forpaeentsundertheageof80receivingreseceonforrectalcancer.

CoCStandard:85%


615NorthBonitaAvenuePanamaCity,FL32401

2017 Annual Report - Bay Medical...Cancer Registry Data Summary of 2016 Statistics In 2016, the...

Documents

Transcript of 2017 Annual Report - Bay Medical...Cancer Registry Data Summary of 2016 Statistics In 2016, the...